The Brilliance of Top Research Scientist, Mikhail Blagosklonny

Mikhail is a scientist, whose main area of study is aging and cancer. Dr. Mikhail is an oncology professor at the Roswell Park Cancer Institute, NY. He earned his M.D in internal medicine and a Ph.D. in experimental medicine and cardiology at the First Pavlov State Medical University located in St. Petersburg. In 2002, Mr. Mikhail was appointed an associate professor of medicine at NY Medical College in Valhalla. Later on, he took up a position as a senior scientist at Ordway Research Institute. It was not until 2009 that he left his job to become an oncology professor at Roswell Park Cancer Institute.

Mikhail’s Interests and Activities

Blagosklonny has an interest in targeted cancer therapies that protect healthy cells from damage. He is also deeply interested in the process of aging and related anti-aging drugs. Additionally, Mikhail is the editor-in-chief of Cell Cycle and Oncotarget. Besides that, he is part of the editorial board for Cell Death and Differentiation. Visit ResearchGate.Net to know more about Mikhail’s latest work.

Mikhail Blagosklonny’s Hypothesis on Aging and Cancer

Mikhail Blagosklonny has come up with a theory on TOR Signaling and its potential role in the treatment of aging and cancer. According to him, aging can be cured with the use of Rapamycin, a popular cancer treatment drug. He proposes using the drug to reverse the negative effects of aging, which leads to an extended life.

Mikhail is renowned the world over as a passionate advocate for the use of Rapamycin. His research work ranges from clinical investigations to molecular and cellular biology. He mainly focuses on the areas of tumor suppressors, selective protection, apoptosis, cell cycle, mitosis, ontogenesis, signal transduction, and anticancer therapeutics.

Other Interests of Mikhail

Mikhail is one of the authors of aging hyper function theory. He also writes about chemotherapeutic engineering and cell cyclotherapy. Thus far, he has printed 300 research articles, reviews, and book chapters published under his name. He is also an associate editor at PLOS ONE, the American Journal of Pathology. Mikhail says that his love for humanity drives his research in anti-aging cures. It is his vision to see a disease free world that drives him to continue his research even when there seems to be only a little progress made. Read more on Impact Journals.